[ZURICH] Swiss pharmaceuticals giant Roche said Monday it reached a deal worth US$4.3 billionĀ  to buy US group Spark Therapeutics, which specialises in the development of gene therapy drugs.

SWISS drugmaker Roche said on Tuesday its Tecentriq medicine will get a speedy review by US regulators in a tough-to-treat form of breast cancer, as it seeks to be the first company to have its...

ROCHE Holding AG's old guard of blockbuster medicines held their own against a new wave of cheaper copycats during the third quarter....

[ZURICH] Swiss drugmaker Roche upped its bet on personalised cancer treatment on Monday, saying it is now ready to sell a blood test around the world that can identify common gene mutations from...

ROCHE faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve its drug Ocrevus for treating a...

LONDON, Sept 10 (Reuters) - Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve its...

[ZURICH] Roche's Alecensa lung cancer medicine became the latest beneficiary of China's efforts to speed up approvals in the world's second-biggest drug market, which is gaining importance for...